Digital women's health and wellbeing applications to trigger disruption across the healthcare continuum with accessible, affordable, and performance-driven solutions for women
LONDON, March 1, 2018 /PRNewswire/ -- Frost & Sullivan's recent analysis,"Femtech: Digital Revolution in Women's Health", finds that female technology (Femtech) is on the cusp of explosive growth. Spurred by almost $1 billion in funding over the last three years and a positive regulatory environment, Femtech is emerging as the next big disruptor in the global healthcare market.
Femtech refers to software, diagnostics, products, and services that harness technology to improve Women's Health. Using a variety of digital health applications and technology that provide end-to-end solutions for key women's health issues, Femtech applications target reproductive, maternal and general women's health and wellness, including mental health issues, elderly care, and chronic and communicable diseases. Self-management and continued engagement is core to managing women's health issues, and Femtech has the power to add value across the care continuum.
"Going forward, it will be critical for medical device, clinical diagnostic, and women's health companies to provide additional value to their customers, which necessitates taking ownership of the value chain. With this objective, they may have to either consider the acquisition of Femtech applications, partnering with specialised Femtech companies or build their own portfolios," noted Shruthi Parakkal, Transformational Health Senior Consultant at Frost & Sullivan. "The end goal is to formulate a marketing strategy exclusively for Femtech, and companies that recognise this need early on will have the first mover advantage."
For further information on Frost & Sullivan's research into the Femtech sector, please visit: http://frost.ly/29m and http://frost.ly/29n
But while the benefits of Femtech are widely recognised, the market is still at a nascent stage and its remarkable growth potential remains unfulfilled, despite having a target customer base of 50% of the global population. This is partially linked to poor visibility and lack of communication about Femtech applications to key decision-makers, including women users and healthcare professionals. Persistent cultural and social barriers, coupled with limited access to healthcare products and services and overall affordability, represent additional pain points for women.
However, the increasingly influential role of women across the healthcare continuum as consumers, decision-makers, healthcare professionals and caregivers, is pushing healthcare companies to actively develop specialised, interactive digital applications for women's health.
Further trends that will drive growth in the Femtech market include:
"With the rise of digital convergence, the overlap between women's health and digital health is increasing, and it is imperative for companies to cater to unmet needs in the industry to capitalise on this strategic sweet spot," said Paljit Sohal, Transformational Health Principal Consultant at Frost & Sullivan. "Femtech, ultimately, needs to be viewed as part of a long-term strategy, rather than a short-term solution."
Femtech: Digital Revolution in Women's Health is part of Frost & Sullivan's Transformational Health Growth Partnership Service programme.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
Contact
Kristina Menzefricke
Corporate Communications -- Frost & Sullivan, Europe
P: +44 (0)208 996 8589
E: kristina.menzefricke@frost.com
http://www.frost.com
